Modality
Cell Therapy
MOA
JAK1i
Target
PARP
Pathway
RNA Splicing
PBCOvarian CaPsoriasis
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
Apr 2024
→ Feb 2028
Phase 1Current
NCT03370834
2,746 pts·Psoriasis
2024-04→2028-02·Recruiting
2,746 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-161.9y awayInterim· Psoriasis
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1
Recruit…
Catalysts
Interim
2028-02-16 · 1.9y away
Psoriasis
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03370834 | Phase 1 | Psoriasis | Recruiting | 2746 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |